Allergan sets date for special meeting but vows to keep fighting Valeant buyout

Put it on the calendar: Allergan has scheduled its special shareholder meeting--key to Valeant's takeover attempt--for Dec. 18. But that doesn't mean it won't continue to fight the very idea in court.

The company has asked a California court to expedite an injunction that would bar Valeant ($VRX) and takeover partner Bill Ackman's Pershing Square Capital Management--now Allergan's largest shareholder--from exercising rights associated with shares that the Botox-maker claims they acquired through insider trading.

Allergan ($AGN) will also be reviewing the validity of shareholder requests for the meeting, the company said. Under Allergan bylaws, the special meeting requires the support of investors holding 25% of shares.

Either of those moves could put a roadblock in the way of Ackman and Valeant's special meeting plans. The takeover duo wants to oust the majority of Allergan's board and install a new, deal-friendly slate to nix the company's takeover defenses.

But the pair say they aren't worried. "We are confident that Allergan's desperate attempts to delay or prevent a special meeting of stockholders will not succeed," they said in a statement. "It is apparent that Allergan fears letting its stockholders have a voice, and we believe that its transparent efforts to prevent that will not stand."

Allergan, naturally, sees the situation a bit differently, and the California drugmaker is fighting to prove that Valeant and Ackman acquired their stake unlawfully. But Allergan already failed once to speed up the litigation process: Last week, a district judge refused to rule on the insider trading case within 120 days, saying he didn't see enough reason for accelerating Allergan's case past the others waiting in line.

- get the release from Allergan

Special Reports: Pharma's top 10 M&A deals of 2013 - Valeant/Bausch + Lomb | The most influential people in biopharma today - J. Michael Pearson, Valeant | 20 Highest-Paid Biopharma CEOs of 2012 - David Pyott, Allergan

Suggested Articles

Turns out Procter & Gamble didn’t want Pfizer’s consumer health unit after all. But it did want Merck KGaA’s.

Private equity firm, in exclusive talks with Sanofi, says it'll invest to pump up Zentiva into an "independent European generics leader."

With suitor Takeda circling Shire, the Dublin-based target has pulled off a deal of its own.